Novan

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline includes SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novan develops products that tap the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. They use its proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. The company is committed to using the power of the human body to create safe and effective treatments. They complement their internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions. It was incorporated in 2008 and is based in Morrisville, North Carolina.

DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”). All shares to be sold in the Offering will be sold by Novan. The Company also expects to grant to the underwriter for the Offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock offered in the public offering. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

Novan Announces Proposed Public Offering of Common Stock

The stock price of Novan Inc (NASDAQ: NOVN) increased by over 5% pre-market. This is why it happened.

NOVN Stock Price Increases Over 5% Pre-Market: Why It Happened

The stock price of Novan Inc (NASDAQ: NOVN) increased by 62.39% yesterday. These are the details.

NOVN Stock Price: 62.39% Increase Explanation

GT Biopharma Inc

Ocugen, Inc.

Vaxart

Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

NOVN stock is flexing 70% gains as the company shows off the wild success of its topical treatment for a common, contagious infection. The post NOVN Stock: The Positive Trial Results Sending Novan Skyrocketing Today appeared first on InvestorPlace.

NOVN Stock: The Positive Trial Results Sending Novan Skyrocketing Today

Novan Inc. (NASDAQ: NOVN) shares are trading higher Friday after the company reported that B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved significance for the primary endpoint with no adverse events. The stock was trending throughout the day on StockTwits and was trading on higher than average volume.

A Technical Look At Novan's Stock Amid 80% Spike

Novan Inc (NASDAQ:NOVN) shares are trading higher by 59% at $14.37 Friday morning after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical significance for the primary endpoint and no serious adverse events were reported. Novan is a clinical-stage biotechnology company that provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases.

Why Novan Shares Are Surging Today

The stock price of Novan Inc (NASDAQ: NOVN) has increased by over 30% pre-market. These are the details.

NOVN Stock Price: Over 30% Increase Pre-Market Explanation

Novan Inc (NASDAQ: NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum is a common, contagious skin infection caused by the molluscipoxvirus.

Novan's Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease

– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 –

Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies –

Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action –

Results from Novan's Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan Inc (NASDAQ: NOVN) announced it is implementing a one-for-ten reverse split of its issued and outstanding common stock. These are the details.

NOVN Stock: 1-For-10 Reverse Split

Evofem Biosciences Inc

Minerva Neurosciences

Obalon Therapeutics

Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May

– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 –

Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

– Topline data on track for readout before the end of Q2 2021 –

Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

Novan, Inc. is a late-clinical-stage biotechnology company specializing in therapeutics based on nitric oxide's naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action. Novan has a pipeline of 6 NO-based therapeutics with 5 in the clinical stage; however, after limited funding, Novan announced a 2021 pause on other trials until SB206's Phase 3 Q2-results.

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

The stock price of Novan Inc (NASDAQ: NOVN) has increased by over 10% pre-market. This is why it happened.

NOVN Stock Price Increased Over 10% Pre-Market: Why It Happened

MORRISVILLE, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Novan to Present at the H.C. Wainwright Global Life Sciences Conference

The stock price of Novan, Inc. (NASDAQ: NOVN) increased by over 28% during intraday trading. This is why it happened.

NOVN Stock Price Increased Over 28% Intraday: Why It Happened

– B-SIMPLE4 pivotal Phase 3 trial evaluating SB206 as a treatment for molluscum contagiosum progressing with top-line efficacy results targeted before the end of Q2 2021 –

Novan Reports Full Year 2020 Financial Results and Provides Corporate Update

– Topline data on track for targeted readout before the end of Q2 2021 –

Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

MORRISVILLE, N.C., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. The notice indicated that, as a result of the closing bid price of the Company's common stock having been at $1.00 per share or greater for at least ten consecutive business days, from January 14, 2021 through January 28, 2021, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

The stock price of Novan Inc (NASDAQ: NOVN) is trading at over 12% pre-market. This is why it happened.

NOVN Stock Price Increases Over 12% Pre-Market: Why It Happened

– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 –

News for Novan Stock (NOVN)